3.75
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RCEL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$3.63
Offen:
$3.73
24-Stunden-Volumen:
119.25K
Relative Volume:
0.53
Marktkapitalisierung:
$114.87M
Einnahmen:
$71.61M
Nettoeinkommen (Verlust:
$-48.59M
KGV:
-2.1416
EPS:
-1.751
Netto-Cashflow:
$-32.88M
1W Leistung:
-2.34%
1M Leistung:
-25.45%
6M Leistung:
-26.61%
1J Leistung:
-53.93%
Avita Medical Inc Stock (RCEL) Company Profile
Firmenname
Avita Medical Inc
Sektor
Branche
Telefon
661-568-1317
Adresse
28159 AVENUE STANFORD, VALENCIA, CA
Compare RCEL vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
RCEL
Avita Medical Inc
|
3.75 | 111.19M | 71.61M | -48.59M | -32.88M | -1.751 |
|
ABT
Abbott Laboratories
|
102.60 | 177.03B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
328.25 | 124.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
86.75 | 110.08B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
62.40 | 93.53B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
80.09 | 45.84B | 6.07B | 1.06B | 1.34B | 1.8063 |
Avita Medical Inc Stock (RCEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-05 | Eingeleitet | Northland Capital | Outperform |
| 2025-11-20 | Hochstufung | BTIG Research | Sell → Neutral |
| 2025-08-08 | Herabstufung | BTIG Research | Neutral → Sell |
| 2024-12-24 | Eingeleitet | D. Boral Capital | Buy |
| 2024-04-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-06-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-03-02 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-27 | Eingeleitet | BofA Securities | Buy |
| 2020-04-21 | Eingeleitet | Oppenheimer | Outperform |
| 2020-03-03 | Eingeleitet | BTIG Research | Buy |
Alle ansehen
Avita Medical Inc Aktie (RCEL) Neueste Nachrichten
AVITA Medical, Inc. (NASDAQ:RCEL) Q4 2025 earnings call transcript - MSN
AVITA Medical Inc at TD Cowen Healthcare Conference Transcript - gurufocus.com
Momentum Shift: Is AVITA Medical Inc stock a good dividend stockWeekly Volume Report & Weekly Top Performers Watchlists - baoquankhu1.vn
AVITA Medical (RCEL) Price Target Decreased by 14.77% to 7.65 - MSN
RCEL Stock Decline Viewed as a Buying Opportunity by Analysts - gurufocus.com
AVH Stock Price and Chart — ASX:AVH - TradingView
If You Invested $1,000 in Avita Medical Inc (RCEL) - Stock Titan
Avita Medical Inc. (NASDAQ:RCEL) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
RCEL Stock Price, Quote & Chart | AVITA MEDICAL INC (NASDAQ:RCEL) - ChartMill
Avita Medical (RCEL) upgraded to buy: Here's what you should know - MSN
Will AVITA Medical Inc. stock recover after earningsDip Buying & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Insider Buying: David O'Toole Acquires Shares of AVITA Medical I - GuruFocus
AVITA Medical (RCEL) CFO adds 1,800 shares in open-market purchase - Stock Titan
Northland Securities Predicts Avita Medical Q1 Earnings - National Today
Growth Recap: Can AVITA Medical Inc maintain sales growthJuly 2025 Pullbacks & Verified Entry Point Signals - baoquankhu1.vn
Northland Capital Markets initiates coverage of AVITA Medical (RCEL) with outperform recommendation - MSN
AVITA Medical (RCEL) director Woody Fralin files initial Form 3 - Stock Titan
Avita Medical (NASDAQ:RCEL) Now Covered by Analysts at Northland Securities - MarketBeat
Avita Medical at TD Cowen Conference: Growth and Strategic Focus By Investing.com - Investing.com Canada
RCEL SEC FilingsAvita Medical Inc 10-K, 10-Q, 8-K Forms - Stock Titan
RCELAVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results - ADVFN Ltd
RCEL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Retail Trends: Can AVITA Medical Inc weather a recession2025 Trade Ideas & Reliable Momentum Entry Alerts - baoquankhu1.vn
Wall Street Analysts Believe Avita Medical (RCEL) Could Rally 29.87%: Here's is How to Trade - Zacks Investment Research
Avita Medical Inc. (NASDAQ:RCEL) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Avita Medical Targets “Progressive” 2026 Growth, Guides $80M-$85M Revenue After Headwind Year - MarketBeat
Wall Street experts predict Avita Medical (RCEL) may surge by 29.87%: Here’s how you can approach trading - Bitget
AVITA Medical to participate at the TD Cowen 46th Annual Health Care Conference - Investing News Network
Avita Medical (NASDAQ:RCEL) CFO David O'toole Purchases 3,000 Shares of Stock - MarketBeat
AVITA Medical (RCEL) CFO awarded RSU and stock option grants - Stock Titan
Avita Medical (RCEL) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Scar Treatment Market Size is Expected to Reach USD 56.30 Billion by 2033; Growth is Propelling Due to the Surging Awareness for Advanced Cosmetic and Reconstructive Procedures Globally - GlobeNewswire Inc.
AVITA Medical Inc Investor Webinar Transcript - gurufocus.com
RCEL: D. Boral Capital Maintains "Buy" Rating and $10 PT | RCEL Stock News - GuruFocus
Avita Medical (NASDAQ:RCEL) Earns "Buy" Rating from D. Boral Capital - MarketBeat
Broker tips 25% upside for this ASX healthcare stock following FY25 earnings results - MSN
Earnings call transcript: Avita Medical Q4 2025 sees steady revenue growth - Investing.com Nigeria
Avita Medical Earnings Call Signals Stabilizing Growth - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), American Well (AMWL) and Avita Medical (RCEL) - The Globe and Mail
Avita's Road to Profitability Is in Sight - Morningstar
AVITA Medical to Host Investor Webinar Briefing - Investing News Network
Ask AVITA Medical’s interim CEO your questions in Feb. 18 investor webinar Q&A - Stock Titan
Finanzdaten der Avita Medical Inc-Aktie (RCEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Avita Medical Inc-Aktie (RCEL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| McNamara Robert | Director |
Aug 28 '25 |
Buy |
4.50 |
10,000 |
45,000 |
86,771 |
| O'Toole David D | CFO |
Aug 26 '25 |
Buy |
4.52 |
2,000 |
9,040 |
31,657 |
| McNamara Robert | Director |
Aug 19 '25 |
Buy |
5.00 |
10,000 |
50,000 |
76,771 |
| O'Toole David D | CFO |
Aug 12 '25 |
Buy |
4.81 |
2,000 |
9,620 |
29,657 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):